Munthe is the founder and Managing Partner of Herkules - a leading Nordic private equity player, and he was Chairman of Pronova Biopharma 2004-2013. Munthe has more than 20 years’ experience as a senior executive from both Norwegian and international business. He is former CEO of Alpharma (listed on the NYSE), NetCom and Nycomed Imaging, and he has extensive board experience. Munthe is through his company North Murray the largest shareholder in Lytix Biopharma AS.
Eidissen has extensive experience as a board member from both private and public companies, and he holds a strong track record in creating shareholder value. Eidissen is the owner and managing director of the consulting and investment company Picasso AS. Eidissen is through Picasso Kapital AS,one of the largest shareholders in Lytix Biopharma AS.
John Sigurd Svendsen
Svendsen brings extensive research experience from work in medical biochemistry, synthetic organic chemistry and medicinal chemistry. He is a co-founder in the company, responsible for the IPR and serves as Senior advisor to the management team. Dr. Svendsen received his PhD from the University of Tromsø, and has been visiting scientist at several distinguished international institutions, including in the laboratory of Professor K.B. Sharpless (Nobel Laureate, Chemistry, 2000) at Massachusetts Institute of Technology. He is a Professor of organic chemistry in the Faculty of Sciences at the University of Tromsø.
Grønås has extensive experience from pharmaceutical research and development in Norwegian pharmaceutical companies including Nycomed, Amersham, Photocure and Algeta. In Algeta she was Senior Vice President Operations and responsible for establishing and operating the production for development and commercial use. Grønås was also project manager for Xofigo and coordinated all the required activities to get drug approval worldwide. Grønås is a board member of BergenBio.
Jurs has broad executive experience from the pharmaceutical sector as well as non-executive experience from several board positions in both public and private companies. Jurs is partner in Pegasus Industrier AS. Prior to Pegasus he was CEO in Stamina Group and CFO and later CEO in Pronova BioPharma Jurs brings with him a versatile experience portfolio from the pharma¬ceuticals, and health and lifestyle industry. Jurs holds a Master of Science in Business and Economics/MBA from the University of Wyoming.
Torlegård has been an advisor on corporate communication since 1998, mainly dealing with financial, corporate and crisis communication. She has worked with a number of Life Science companies, among others Sobi, Karo Bio, Orexo and Medivir. Her record of accomplishment also encompasses around 15 IPO’s – Orexo possibly the most prominent within the Life Science sector. She has also advised extensively on communication to support fund raising and M&A. She is currently a member of the Board of Directors for Nanologica - drug delivery and analytical chromatography. Lena Torlegård holds a degree in Business Administration from Stockholm School of Economics.
Debasish F. Roychowdhury
Roychowdhury is a recognized leader in the pharmaceutical industry. He is an oncologist with a background in R&D, regulatory affairs and commercial operations. He is President of Nirvan Consultants and serves in senior advisory roles for biotechnology companies. He is the acting CMO (Chief Medical Officer) for Ra Pharmaceuticals and was the CMO at Seragon Pharmaceuticals. From 2009 to 2013, Roychowdhury was Senior Vice President and Head of the Global Oncology Division at Sanofi. Prior to that, he was Vice President and head of Clinical Development at GlaxoSmithKline. Roychowdhury directed the Oncology global regulatory group at Eli Lilly and Company. During his tenure in industry, he has been involved in the approval of nine new drugs, several IND filings and supplementary approvals.